.png)
Sylvain Briault, MD, PhD
Dr. Sylvain Briault is the scientific co-founder of Kaerus Bioscience. A geneticist by training, he is an expert in neurodevelopmental genetics with over 30 years of experience in research on neurodevelopmental disorders (NDD), with a primarily focus on BKCa (KCNMA1) channelopathies and Fragile X syndrome (FXS).
He began his career in the Department of Genetics at the Medical School Institut National de la Santé et de la Recherche Médicale (INSERM U930), Tours (France), where he identified several NDD-related genes, including KCNMA1. Thirteen years later, he moved to the Regional Hospital of Orléans (France), where he established the Department of Genetics and a research team dedicated to neurogenetics (CNRS UMR7355). The close integration of clinical genetics with preclinical research enabled the genetic validation of BKCa channels as a therapeutic target for FXS, as well as proof of concept for the efficacy of BKCa channel openers in mouse models.
In parallel, Dr. Olivier Perche, the second scientific founder of Kaerus, identified visual neurosensory disorders with phenotypic expression in FXS mouse models and later in patients. Together, these findings led to the creation of Kaerus Bioscience, with the mission of developing therapeutic solutions for individuals with FXS and, more broadly, for patients with BKCa channelopathies.
Most recently, Dr. Briault transitioned from CNRS to Inserm to join a Technological Research Accelerator (ART US55 mRNA) dedicated to mRNA-based therapies.
Olivier Perche, PhD
Dr. Olivier Perche is the scientific co-founder of Kaerus Bioscience. A biomedical researcher by training, he is an expert in molecular genetics and neurodevelopmental disorders, with nearly 20 years of experience bridging clinical diagnostics, translational research, and therapeutic innovation.
He currently serves as Head of the Molecular Biology Platform in the Department of Genetics at Centre Hospitalier Universitaire (CHU) d'Orléans, a position he has held since 2020. He is also a researcher on the Innovative Therapies & Nanomedicine (InTherNa) team at the LI²RSO laboratory (Université–CHU Orléans). In September 2025, he will be appointed Associate Professor of Medicine and Hospital Practitioner (Maître de Conférences des Universités – Praticien Hospitalier, MCU-PH) at both University of Orléans and CHU of Orléans.
He began his career with a PhD in Neuroscience at the Université d’Auvergne, where his research on retinal degenerations led to the identification of novel therapeutic targets and was recognized by the French National Academy of Medicine. He then joined the CNRS–University–CHR Orléans unit (UMR7355, Neurogenetics team), where he became deputy group leader. His research focused on Fragile X syndrome (FXS), leading to his seminal work implicating BKCa channels as a promising therapeutic target for this syndrome.
In parallel, Dr. Perche played a pivotal role in the hospital setting as Head of the Molecular Biology Platform at CHU Orléans, implementing next-generation sequencing diagnostics and large-scale molecular testing (SNP array, NGS), including COVID-19 screening. His dual expertise in clinical genetics and research enabled discoveries linking visual neurosensory impairments in FXS from mouse models to human patients. These findings, together with Dr. Sylvain Briault, led to the creation of Kaerus Bioscience, dedicated to developing therapeutic solutions for individuals with FXS and BKCa channelopathies.
Currently, Dr. Perche continues his academic activities within the InTherNa team at the LI²RSO laboratory (Université–CHU Orléans) and as a member of Inserm’s Technological Research Accelerator on mRNA therapies (ART US55 mRNA). His current projects focus on investigating visual dysfunctions in neurodevelopmental disorders, genetic ophthalmologic diseases, and contributing to RNA-based therapeutic innovations.